RVV RVVTF 31R - Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.